Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Warfarin for Pulmonary Hypertension in Sickle Cell Disease
NCT01036802Phase 2Terminated
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Dec 2009
- Primary completion
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of warfarin in pulmonary hypertension (PH), sponsored by University of North Carolina at Chapel Hill. Primary endpoint: Pulmonary Artery Systolic Pressure at 12 months. Started Dec 2009; status: terminated.
02
Drugs
warfarin
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT01036802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01036802.